Shandong Pharmaceutical Glass Co., Ltd Logo

Shandong Pharmaceutical Glass Co., Ltd

600529.SS

(3.5)
Stock Price

25,18 CNY

8.98% ROA

11.39% ROE

22.67x PER

Market Cap.

19.616.429.840,00 CNY

9.13% DER

1.35% Yield

16.96% NPM

Shandong Pharmaceutical Glass Co., Ltd Stock Analysis

Shandong Pharmaceutical Glass Co., Ltd Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Shandong Pharmaceutical Glass Co., Ltd Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

2 Revenue Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

3 Net Profit Growth

This company's net profit has consistently grown over the last five years, indicating a strong financial performance and making it an attractive investment opportunity.

4 Assets Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

5 Dividend

With a solid track record of dividend payments over the past five years, the company has established itself as a dependable choice for investors seeking consistent income.

6 ROE

ROE in an average range (10.31%) suggests satisfactory profitability and decent utilization of shareholders' equity.

7 ROA

The stock's ROA (8.42%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

8 PBV

The stock's PBV ratio (2.28x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

9 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (143), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

10 Graham Number

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

11 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

Shandong Pharmaceutical Glass Co., Ltd Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Shandong Pharmaceutical Glass Co., Ltd Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Shandong Pharmaceutical Glass Co., Ltd Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Shandong Pharmaceutical Glass Co., Ltd Revenue
Year Revenue Growth
1999 231.107.107
2000 293.114.742 21.15%
2001 350.108.854 16.28%
2002 422.318.260 17.1%
2003 467.989.529 9.76%
2004 560.177.649 16.46%
2005 672.138.979 16.66%
2006 826.714.232 18.7%
2007 1.012.129.757 18.32%
2008 1.158.292.067 12.62%
2009 1.242.158.522 6.75%
2010 1.513.418.307 17.92%
2011 1.397.177.995 -8.32%
2012 1.468.092.831 4.83%
2013 1.544.544.952 4.95%
2014 1.691.112.456 8.67%
2015 1.723.207.165 1.86%
2016 2.057.473.059 16.25%
2017 2.330.488.351 11.71%
2018 2.584.627.161 9.83%
2019 2.992.346.751 13.63%
2020 3.427.069.472 12.68%
2021 3.875.304.663 11.57%
2022 4.187.279.279 7.45%
2023 5.005.524.167 16.35%
2023 4.935.300.438 -1.42%
2024 5.205.471.324 5.19%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Shandong Pharmaceutical Glass Co., Ltd Research and Development Expenses
Year Research and Development Expenses Growth
1999 0
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 1.514.459 100%
2011 6.298.541 75.96%
2012 1.870.810 -236.67%
2013 1.884.375 0.72%
2014 2.470.047 23.71%
2015 3.782.742 34.7%
2016 16.826.038 77.52%
2017 75.042.687 77.58%
2018 85.235.086 11.96%
2019 131.988.072 35.42%
2020 141.323.009 6.61%
2021 136.802.520 -3.3%
2022 138.937.775 1.54%
2023 123.223.117 -12.75%
2023 119.315.755 -3.27%
2024 131.488.980 9.26%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Shandong Pharmaceutical Glass Co., Ltd General and Administrative Expenses
Year General and Administrative Expenses Growth
1999 17.893.810
2000 23.070.120 22.44%
2001 22.140.703 -4.2%
2002 24.435.988 9.39%
2003 35.250.194 30.68%
2004 40.030.575 11.94%
2005 45.625.377 12.26%
2006 57.559.441 20.73%
2007 43.014.387 -33.81%
2008 57.170.546 24.76%
2009 74.153.649 22.9%
2010 12.639.117 -486.7%
2011 18.472.656 31.58%
2012 14.117.876 -30.85%
2013 22.307.336 36.71%
2014 13.795.823 -61.7%
2015 21.570.891 36.04%
2016 24.866.224 13.25%
2017 20.324.254 -22.35%
2018 17.681.886 -14.94%
2019 16.641.365 -6.25%
2020 20.132.469 17.34%
2021 20.550.246 2.03%
2022 25.175.254 18.37%
2023 404.191.622 93.77%
2023 35.359.519 -1043.09%
2024 -181.086.766 119.53%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Shandong Pharmaceutical Glass Co., Ltd EBITDA
Year EBITDA Growth
1999 48.198.836
2000 50.940.123 5.38%
2001 84.129.194 39.45%
2002 108.924.209 22.76%
2003 138.013.664 21.08%
2004 169.821.831 18.73%
2005 190.168.009 10.7%
2006 212.039.166 10.31%
2007 240.746.537 11.92%
2008 264.520.764 8.99%
2009 279.962.629 5.52%
2010 315.055.991 11.14%
2011 274.421.282 -14.81%
2012 313.413.778 12.44%
2013 326.237.766 3.93%
2014 329.409.023 0.96%
2015 389.565.825 15.44%
2016 477.806.440 18.47%
2017 472.107.166 -1.21%
2018 616.338.581 23.4%
2019 724.526.433 14.93%
2020 920.528.449 21.29%
2021 965.357.896 4.64%
2022 1.042.479.519 7.4%
2023 1.073.010.491 2.85%
2023 1.170.587.810 8.34%
2024 1.497.316.960 21.82%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Shandong Pharmaceutical Glass Co., Ltd Gross Profit
Year Gross Profit Growth
1999 86.391.399
2000 100.362.322 13.92%
2001 129.161.348 22.3%
2002 157.268.449 17.87%
2003 181.316.046 13.26%
2004 212.062.644 14.5%
2005 233.290.232 9.1%
2006 276.864.388 15.74%
2007 300.848.085 7.97%
2008 339.302.765 11.33%
2009 388.171.582 12.59%
2010 458.110.084 15.27%
2011 383.471.831 -19.46%
2012 407.498.764 5.9%
2013 439.609.399 7.3%
2014 447.647.594 1.8%
2015 539.471.009 17.02%
2016 674.969.755 20.07%
2017 750.889.320 10.11%
2018 930.154.208 19.27%
2019 1.104.350.442 15.77%
2020 1.149.995.800 3.97%
2021 1.147.743.882 -0.2%
2022 1.124.012.478 -2.11%
2023 1.536.841.211 26.86%
2023 1.296.624.904 -18.53%
2024 1.673.209.600 22.51%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Shandong Pharmaceutical Glass Co., Ltd Net Profit
Year Net Profit Growth
1999 28.157.644
2000 30.452.642 7.54%
2001 38.797.288 21.51%
2002 54.752.953 29.14%
2003 70.197.205 22%
2004 75.658.066 7.22%
2005 82.484.076 8.28%
2006 94.055.248 12.3%
2007 111.013.512 15.28%
2008 141.991.489 21.82%
2009 144.361.875 1.64%
2010 171.330.127 15.74%
2011 132.532.983 -29.27%
2012 119.828.142 -10.6%
2013 122.333.707 2.05%
2014 124.702.667 1.9%
2015 145.407.381 14.24%
2016 189.604.926 23.31%
2017 262.758.070 27.84%
2018 358.209.968 26.65%
2019 458.687.262 21.91%
2020 564.439.557 18.74%
2021 591.088.499 4.51%
2022 618.287.086 4.4%
2023 914.916.978 32.42%
2023 775.802.014 -17.93%
2024 1.017.508.980 23.75%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Shandong Pharmaceutical Glass Co., Ltd Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1999 0
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 1 0%
2019 1 0%
2020 1 0%
2021 1 0%
2022 1 100%
2023 0 0%
2023 1 100%
2024 2 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Shandong Pharmaceutical Glass Co., Ltd Free Cashflow
Year Free Cashflow Growth
2001 3.286.657
2002 -3.224.142 201.94%
2003 -212.391.619 98.48%
2004 -149.814.595 -41.77%
2005 -41.003.054 -265.37%
2006 7.874.247 620.72%
2007 -38.190.578 120.62%
2008 -66.636.499 42.69%
2009 130.828.383 150.93%
2010 16.642.970 -686.09%
2011 57.099.335 70.85%
2012 -93.576.594 161.02%
2013 118.106.875 179.23%
2014 133.107.299 11.27%
2015 234.517.798 43.24%
2016 309.949.670 24.34%
2017 244.898.719 -26.56%
2018 118.388.416 -106.86%
2019 7.363.448 -1507.79%
2020 30.810.979 76.1%
2021 -58.816.878 152.38%
2022 -458.271.048 87.17%
2023 97.649.358 569.3%
2023 413.211.227 76.37%
2024 156.455.019 -164.11%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Shandong Pharmaceutical Glass Co., Ltd Operating Cashflow
Year Operating Cashflow Growth
2001 28.603.697
2002 109.261.606 73.82%
2003 59.348.664 -84.1%
2004 -3.698.860 1704.51%
2005 44.086.953 108.39%
2006 78.468.091 43.82%
2007 122.632.735 36.01%
2008 91.758.958 -33.65%
2009 249.269.436 63.19%
2010 217.011.545 -14.86%
2011 274.626.291 20.98%
2012 28.519.302 -862.95%
2013 268.597.934 89.38%
2014 266.634.293 -0.74%
2015 389.634.256 31.57%
2016 506.528.107 23.08%
2017 411.962.940 -22.95%
2018 465.773.178 11.55%
2019 599.051.285 22.25%
2020 566.009.160 -5.84%
2021 750.440.353 24.58%
2022 252.442.324 -197.27%
2023 311.145.322 18.87%
2023 1.084.741.692 71.32%
2024 303.698.518 -257.18%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Shandong Pharmaceutical Glass Co., Ltd Capital Expenditure
Year Capital Expenditure Growth
2001 25.317.040
2002 112.485.748 77.49%
2003 271.740.283 58.61%
2004 146.115.735 -85.98%
2005 85.090.007 -71.72%
2006 70.593.843 -20.53%
2007 160.823.313 56.1%
2008 158.395.457 -1.53%
2009 118.441.053 -33.73%
2010 200.368.574 40.89%
2011 217.526.955 7.89%
2012 122.095.896 -78.16%
2013 150.491.059 18.87%
2014 133.526.994 -12.7%
2015 155.116.458 13.92%
2016 196.578.437 21.09%
2017 167.064.220 -17.67%
2018 347.384.762 51.91%
2019 591.687.837 41.29%
2020 535.198.181 -10.55%
2021 809.257.231 33.87%
2022 710.713.372 -13.87%
2023 213.495.964 -232.89%
2023 671.530.465 68.21%
2024 147.243.499 -356.07%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Shandong Pharmaceutical Glass Co., Ltd Equity
Year Equity Growth
1999 158.782.706
2000 188.325.654 15.69%
2001 224.337.218 16.05%
2002 650.315.125 65.5%
2003 725.230.654 10.33%
2004 797.185.016 9.03%
2005 861.573.416 7.47%
2006 924.737.531 6.83%
2007 1.306.727.491 29.23%
2008 1.452.558.965 10.04%
2009 1.593.219.837 8.83%
2010 1.745.349.582 8.72%
2011 1.849.746.623 5.64%
2012 1.940.346.924 4.67%
2013 2.029.982.702 4.42%
2014 2.125.618.617 4.5%
2015 2.237.460.758 5%
2016 3.043.601.049 26.49%
2017 3.250.316.273 6.36%
2018 3.525.714.331 7.81%
2019 3.867.778.257 8.84%
2020 4.255.887.953 9.12%
2021 4.670.303.783 8.87%
2022 6.961.679.480 32.91%
2023 7.375.091.902 5.61%
2023 7.534.508.778 2.12%
2024 7.742.308.686 2.68%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Shandong Pharmaceutical Glass Co., Ltd Assets
Year Assets Growth
1999 353.448.934
2000 394.610.019 10.43%
2001 467.235.781 15.54%
2002 943.593.775 50.48%
2003 1.036.029.176 8.92%
2004 1.232.035.467 15.91%
2005 1.425.842.940 13.59%
2006 1.630.602.467 12.56%
2007 1.871.385.404 12.87%
2008 1.987.075.896 5.82%
2009 2.216.731.123 10.36%
2010 2.523.689.847 12.16%
2011 2.494.549.671 -1.17%
2012 2.612.144.674 4.5%
2013 2.705.463.004 3.45%
2014 2.818.180.079 4%
2015 2.973.070.867 5.21%
2016 3.904.225.444 23.85%
2017 4.180.160.012 6.6%
2018 4.623.713.518 9.59%
2019 5.170.275.537 10.57%
2020 5.621.418.334 8.03%
2021 6.409.715.397 12.3%
2022 8.784.252.529 27.03%
2023 9.018.969.161 2.6%
2023 9.318.721.550 3.22%
2024 9.891.173.050 5.79%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Shandong Pharmaceutical Glass Co., Ltd Liabilities
Year Liabilities Growth
1999 194.666.227
2000 206.284.363 5.63%
2001 242.898.562 15.07%
2002 293.278.649 17.18%
2003 310.798.520 5.64%
2004 434.850.449 28.53%
2005 564.269.523 22.94%
2006 705.864.935 20.06%
2007 564.657.911 -25.01%
2008 534.516.930 -5.64%
2009 623.511.286 14.27%
2010 778.340.264 19.89%
2011 644.803.048 -20.71%
2012 671.797.750 4.02%
2013 675.480.302 0.55%
2014 692.561.460 2.47%
2015 735.610.107 5.85%
2016 860.624.394 14.53%
2017 929.843.738 7.44%
2018 1.097.999.187 15.31%
2019 1.302.497.280 15.7%
2020 1.365.530.380 4.62%
2021 1.739.411.613 21.49%
2022 1.822.573.049 4.56%
2023 1.643.877.259 -10.87%
2023 1.726.592.238 4.79%
2024 2.078.131.666 16.92%

Shandong Pharmaceutical Glass Co., Ltd Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
7.69
Net Income per Share
1.3
Price to Earning Ratio
22.67x
Price To Sales Ratio
3.84x
POCF Ratio
15.7
PFCF Ratio
29.25
Price to Book Ratio
2.53
EV to Sales
3.72
EV Over EBITDA
16.55
EV to Operating CashFlow
15.22
EV to FreeCashFlow
28.34
Earnings Yield
0.04
FreeCashFlow Yield
0.03
Market Cap
19,62 Bil.
Enterprise Value
19,01 Bil.
Graham Number
18.5
Graham NetNet
4.25

Income Statement Metrics

Net Income per Share
1.3
Income Quality
1.44
ROE
0.11
Return On Assets
0.09
Return On Capital Employed
0.12
Net Income per EBT
0.84
EBT Per Ebit
1.08
Ebit per Revenue
0.19
Effective Tax Rate
0.16

Margins

Sales, General, & Administrative to Revenue
0.01
Research & Developement to Revenue
0.03
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.3
Operating Profit Margin
0.19
Pretax Profit Margin
0.2
Net Profit Margin
0.17

Dividends

Dividend Yield
0.01
Dividend Yield %
1.35
Payout Ratio
0
Dividend Per Share
0.4

Operating Metrics

Operating Cashflow per Share
1.88
Free CashFlow per Share
1.01
Capex to Operating CashFlow
0.46
Capex to Revenue
0.11
Capex to Depreciation
2.16
Return on Invested Capital
0.09
Return on Tangible Assets
0.09
Days Sales Outstanding
129.34
Days Payables Outstanding
77.13
Days of Inventory on Hand
109.85
Receivables Turnover
2.82
Payables Turnover
4.73
Inventory Turnover
3.32
Capex per Share
0.87

Balance Sheet

Cash per Share
4,52
Book Value per Share
11,77
Tangible Book Value per Share
11.4
Shareholders Equity per Share
11.67
Interest Debt per Share
1.07
Debt to Equity
0.09
Debt to Assets
0.07
Net Debt to EBITDA
-0.53
Current Ratio
2.87
Tangible Asset Value
7,56 Bil.
Net Current Asset Value
3,89 Bil.
Invested Capital
7774185035
Working Capital
3,89 Bil.
Intangibles to Total Assets
0.03
Average Receivables
1,79 Bil.
Average Payables
0,72 Bil.
Average Inventory
1057095607
Debt to Market Cap
0.04

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Shandong Pharmaceutical Glass Co., Ltd Dividends
Year Dividends Growth
2002 0
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 1 0%

Shandong Pharmaceutical Glass Co., Ltd Profile

About Shandong Pharmaceutical Glass Co., Ltd

Shandong Pharmaceutical Glass Co., Ltd manufactures and sells pharmaceutical glass packaging and butyl rubber series products in China. It offers pharma glass packaging products, such as molded injection glass vials, food-grade bottles, clear cosmetic bottles, cobalt blue and green bottles, tubular glass vials, ampoules, glass tubing products, amber glass bottles, and other borosilicate glass products; butyl rubber stoppers; prefilled syringes, plastic and aluminum caps, plastic caps, and plastic bottles; and dropper caps and Teflon coated rubber stoppers. The company sells its products to the pharmaceutical, food, and cosmetic glass packaging industries. It also exports its products to Europe, the United States, Russia, Japan, Korea, Southeast Asia, and other countries. Shandong Pharmaceutical Glass Co., Ltd was founded in 1970 and is based in Zibo, China.

CEO
Mr. Gang Chen
Employee
6.473
Address
Yaobo Road
Zibo, 256100

Shandong Pharmaceutical Glass Co., Ltd Executives & BODs

Shandong Pharmaceutical Glass Co., Ltd Executives & BODs
# Name Age
1 Mr. Gang Chen
Executive Deputy GM & Director
70
2 Mr. Yizhao Song
Chief Financial Officer
70
3 Mr. Yucai Su
Deputy General Manager
70
4 Mr. Wansheng He
Deputy General Manager
70
5 Mr. Bin Du
Deputy General Manager
70
6 Mr. Xingjun Wang
Deputy GM & Director
70
7 Mr. Jun Zhang
GM & Director
70

Shandong Pharmaceutical Glass Co., Ltd Competitors